My ePortfolio Register   

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.12
Views: 14979

Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

Dr Kimberly Blackwell interviewed by Professor David Miles, Mount Vernon Hospital, London, UK, about the EMILIA trial at the ASCO 2012 Annual Meeting in Chicago, June 2012.


The EMILIA trial is a phase III randomised study of the investigational agent trastuzumab emtansine (T-DM1) vs. standard therapy using capecitabine and lapatinib.


Dr Blackwell and her team found significant and clinically meaningful improvement in progression-free survival with T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab. 

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence